Background: Claudin 18.2 (CLDN18.2) is contained within normal gastric mucosa epithelial tight junctions; upon malignant transformation, CLDN18.2 epitopes become exposed. Zolbetuximab, a chimeric monoclonal antibody, mediates specific killing of CLDN18.2-positive cells through immune effector mechanisms.
Patients And Methods: The FAST study enrolled advanced gastric/gastro-oesophageal junction and oesophageal adenocarcinoma patients (aged ≥18 years) with moderate-to-strong CLDN18.2 expression in ≥40% tumour cells. Patients received first-line epirubicin + oxaliplatin + capecitabine (EOX, arm 1, n = 84) every 3 weeks (Q3W), or zolbetuximab + EOX (loading dose, 800 mg/m then 600 mg/m Q3W) (arm 2, n = 77). Arm 3 (exploratory) was added after enrolment initiation (zolbetuximab + EOX 1000 mg/m Q3W, n = 85). The primary endpoint was progression-free survival (PFS) and overall survival (OS) was a secondary endpoint.
Results: In the overall population, both PFS [hazard ratio (HR) = 0.44; 95% confidence interval (CI), 0.29-0.67; P < 0.0005] and OS (HR = 0.55; 95% CI, 0.39-0.77; P < 0.0005) were significantly improved with zolbetuximab + EOX (arm 2) compared with EOX alone (arm 1). This significant PFS benefit was retained in patients with moderate-to-strong CLDN18.2 expression in ≥70% of tumour cells (HR = 0.38; 95% CI, 0.23-0.62; P < 0.0005). Significant improvement in PFS was also reported in the overall population of arm 3 versus arm 1 (HR = 0.58; 95% CI, 0.39-0.85; P = 0.0114) but not in high CLDN18.2-expressing patients; no significant improvement in OS was observed in either population. Most adverse events (AEs) related to zolbetuximab + EOX (nausea, vomiting, neutropenia, anaemia) were grade 1-2. Grade ≥3 AEs showed no substantial increases overall (zolbetuximab + EOX versus EOX alone).
Conclusions: In advanced gastric/gastro-oesophageal junction and oesophageal adenocarcinoma patients expressing CLDN18.2, adding zolbetuximab to first-line EOX provided longer PFS and OS versus EOX alone. Zolbetuximab + EOX was generally tolerated and AEs were manageable. Zolbetuximab 800/600 mg/m is being evaluated in phase III studies based on clinical benefit observed in the overall population and in patients with moderate-to-strong CLDN18.2 expression in ≥70% of tumour cells.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.annonc.2021.02.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
1,4-Benzodioxane Substituted Aza-BODIPY: Towards Photostable yet Efficient Triplet Photosensitizer.
Chem Asian J
December 2024
Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387, Kraków, Poland.
Article Synopsis
- Researchers synthesized a new type of aza-BODIPY with special substituents that enhance its light-absorbing properties and allow it to maintain a long-lived excited state.
- The compound produced strong singlet oxygen formation in tests and absorbed light in the therapeutic range (678 nm), making it potentially effective for medical applications.
- It demonstrated excellent stability under light and heat, indicating its viability for future uses in photocatalysis and photodynamic therapy.
A Four-Coordinate End-On Superoxocopper(II) Complex: Probing the Link between Coordination Number and Reactivity.
J Am Chem Soc
August 2024
Division of Chemistry and Biological Chemistry, School of Chemistry, Chemical Engineering and Biotechnology, Nanyang Technological University, 21 Nanyang Link, 637371 Singapore.
Although the reactivity of five-coordinate end-on superoxocopper(II) complexes, Cu(η-O), is dominated by hydrogen atom transfer, the majority of four-coordinate Cu(η-O) complexes published thus far display nucleophilic reactivity. To investigate the origin of this difference, we have developed a four-coordinate end-on superoxocopper(II) complex supported by a sterically encumbered bis(2-pyridylmethyl)amine ligand, dpb-BPA (), and compared its substrate reactivity with that of a five-coordinate end-on superoxocopper(II) complex ligated by a similarly substituted tris(2-pyridylmethyl)amine, dpb-TMPA (). Kinetic isotope effect (KIE) measurements and correlation of second-order rate constants ('s) versus oxidation potentials () for a range of phenols indicates that the complex [Cu(η-O)()] reacts with phenols via a similar hydrogen atom transfer (HAT) mechanism to [Cu(η-O)()].
View Article and Find Full Text PDFStable Meisenheimer Complexes as Powerful Photoreductants Readily Obtained from Aza-Hetero Aromatic Compounds.
Angew Chem Int Ed Engl
October 2024
Dipartimento di Chimica "Giacomo Ciamician" Alma Mater Studiorum-, Università di Bologna, Via Gobetti 85, 40129, Bologna, Italy.
Excited states of radical anions derived from the photoreduction of stable organic molecules are suggested to serve as potent reductants. However, excited states of these species are too short-lived to allow bimolecular quenching processes. Recently, the singlet excited state of Meisenheimer complexes, which possess a long-lived excited state, was identified as the competent species for the reduction of challenging organic substrates (-2.
View Article and Find Full Text PDFSystemic Treatment Strategies and Outcomes of Patients With Synchronous Peritoneal Metastases of Gastric Origin: A Nationwide Population-Based Study.
J Natl Compr Canc Netw
July 2024
1Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Background: Palliative systemic treatment is currently standard of care for metastatic gastric cancer. However, patients with peritoneal metastases of gastric origin are often underrepresented in clinical studies due to unmeasurable radiologic disease. This study describes the systemic treatment strategies and outcomes in patients with peritoneal metastases in a nationwide real-world setting.
View Article and Find Full Text PDFA Novel 4H-SiC Asymmetric MOSFET with Step Trench.
Micromachines (Basel)
May 2024
School of Electrical Engineering, Southwest Jiaotong University, Chengdu 611756, China.
In this article, a silicon carbide (SiC) asymmetric MOSFET with a step trench (AST-MOS) is proposed and investigated. The AST-MOS features a step trench with an extra electron current path on one side, thereby increasing the channel density of the device. A thick oxide layer is also employed at the bottom of the step trench, which is used as a new voltage-withstanding region.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!